|
Maya's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
The FDA rejected Summit’s lung cancer drug, while autoimmune programs hit setbacks and Lilly prepares obesity data on Zepbound, Foundayo and retatrutide.
The top 10 stories from Fri Nov 13, 2026 06:59 AM to Mon Nov 16, 2026 07:00 AM
Generated November 16, 2026 at 7:00 AM
|
|
|
#1 Summit's PD-1xVEGF rejected by FDA in lung cancer Published 2026-11-15 The FDA denied approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, preventing its U.S. launch after its 2024 availability in China. Covered by: biospace.com, insights.citeline.com, statnews.com, endpoints.news, fiercebiotech.com |
#2 Deaths, failed trials and other recent setbacks in the autoimmune space Published 2026-11-16 Novartis, Bristol Myers Squibb, argenx and other drugmakers have faced autoimmune-program setbacks, including discontinued assets, strategic pauses and safety concerns. Covered by: biospace.com |
#3 Global Sarcoma Therapy Now Available in Thailand Published 2026-11-15 Thailand’s FDA approved YONDELIS (trabectedin) for adults with advanced soft-tissue sarcoma who failed or cannot receive anthracycline and ifosfamide treatment. Covered by: prnewswire.com |
#4 IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors Published 2026-11-15 IDEAYA Biosciences nominated IDE101, a potential first-in-class candidate targeting CDKN2A-deficient solid tumors, after preclinical activity alone and with RAS and PRMT5 inhibitors. Covered by: prnewswire.com |
#5 Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026 Published 2026-11-14 Servier will present up to four years of follow-up data from its Phase 2 FIREFLY-1 study of tovorafenib in children with relapsed or refractory BRAF-altered low-grade glioma at SNO 2026. Covered by: prnewswire.com |
#6 Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale Published 2026-11-14 Lilly plans to present ObesityWeek 2026 data on Zepbound, Foundayo, EloraTZP and retatrutide, including Phase 2 results showing weight loss and A1C improvements with EloraTZP. Covered by: prnewswire.com |
#7 PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO Published 2026-11-13 PharmaLogic is acquiring Lantheus’s CDMO unit and New Jersey production plant, less than two years after Lantheus bought the assets. Covered by: biospace.com |
#8 Moderna readies commercial cancer vaccine production ahead of FDA filing Published 2026-11-13 Moderna says it is preparing to produce thousands of doses of its Merck-partnered cancer vaccine ahead of an FDA marketing application filing by year-end. Covered by: endpoints.news |
#9 Innovent Announces Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-squamous Non-Small Cell Lung Cancer Published 2026-11-16 The EMA’s CHMP recommended Zybrivo (sintilimab) for first-line treatment of non-squamous non-small cell lung cancer, marking Innovent’s first European regulatory milestone. Covered by: prnewswire.com |
#10 Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology Published 2026-11-14 In the REDEFINE 9 trial, Novo Nordisk’s investigational CagriSema produced estimated average weight loss of about 21% at 68 weeks, versus 2% with placebo, among adults with overweight or obesity. Covered by: prnewswire.com |